Schwab Charles Investment Management Inc. lifted its holdings in shares of Xencor (NASDAQ:XNCR) by 7.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 201,431 shares of the biopharmaceutical company’s stock after acquiring an additional 13,970 shares during the period. Schwab Charles Investment Management Inc. owned 0.43% of Xencor worth $4,416,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also modified their holdings of XNCR. The Manufacturers Life Insurance Company raised its position in shares of Xencor by 6.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,771 shares of the biopharmaceutical company’s stock worth $629,000 after acquiring an additional 1,673 shares in the last quarter. Nationwide Fund Advisors raised its position in shares of Xencor by 4.5% during the 3rd quarter. Nationwide Fund Advisors now owns 62,180 shares of the biopharmaceutical company’s stock worth $1,425,000 after acquiring an additional 2,676 shares in the last quarter. Prudential Financial Inc. raised its position in shares of Xencor by 59.6% during the 3rd quarter. Prudential Financial Inc. now owns 35,100 shares of the biopharmaceutical company’s stock worth $804,000 after acquiring an additional 13,106 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in shares of Xencor during the 3rd quarter worth about $201,000. Finally, Swiss National Bank raised its position in shares of Xencor by 5.2% during the 3rd quarter. Swiss National Bank now owns 66,400 shares of the biopharmaceutical company’s stock worth $1,522,000 after acquiring an additional 3,300 shares in the last quarter. 79.49% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have recently weighed in on XNCR. Zacks Investment Research raised Xencor from a “sell” rating to a “hold” rating in a research report on Saturday, March 17th. Nomura cut their target price on Xencor to $28.00 and set a “neutral” rating on the stock in a research report on Thursday. Leerink Swann reissued an “outperform” rating and set a $36.00 target price on shares of Xencor in a research report on Wednesday, March 28th. Cantor Fitzgerald reissued a “buy” rating and set a $37.00 target price on shares of Xencor in a research report on Thursday, March 29th. Finally, ValuEngine raised Xencor from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $35.17.
XNCR traded down $0.09 during trading on Friday, hitting $28.41. 291,263 shares of the stock were exchanged, compared to its average volume of 544,687. The firm has a market cap of $1,542.72, a price-to-earnings ratio of -27.06 and a beta of 1.51. Xencor has a 1-year low of $18.55 and a 1-year high of $34.63.
Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.02. The company had revenue of $10.94 million for the quarter, compared to analyst estimates of $15.65 million. Xencor had a negative return on equity of 16.62% and a negative net margin of 137.35%. sell-side analysts predict that Xencor will post -2.09 earnings per share for the current fiscal year.
In other news, insider Edgardo Baracchini, Jr. sold 40,000 shares of the business’s stock in a transaction that occurred on Thursday, March 15th. The stock was sold at an average price of $30.89, for a total value of $1,235,600.00. Following the transaction, the insider now owns 40,000 shares of the company’s stock, valued at $1,235,600. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Paul A. Foster sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $26.03, for a total value of $260,300.00. Following the completion of the transaction, the insider now directly owns 12,419 shares in the company, valued at approximately $323,266.57. The disclosure for this sale can be found here. In the last three months, insiders sold 105,000 shares of company stock worth $3,101,550. Corporate insiders own 4.03% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Schwab Charles Investment Management Inc. Has $4.42 Million Position in Xencor (NASDAQ:XNCR)” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US and international copyright and trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/08/xencor-inc-xncr-shares-bought-by-schwab-charles-investment-management-inc.html.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.